b. Screening and Diagnosing Gestational Diabetes – Key Question 2

IV.	Coder Information
RefID:	

D. CID.	T: A	3 7 -				
RefID:	First Author:		Year:			
DE initials:	DV initials:	Oth	Other KQs: \square 1; \square 3; \square 4; \square 5			
V. Study Characteristi	ics					
Country:	Publication type:		Study design:			
Centers:	Recruitment start date (e.g	., Jan 1998):	Recruitment end date (e.g., Feb 2000):			
Funding: □Industry; □Go	vernment; □Academic; □	Foundation;	\square No funding; \square	Other; □ND		
If industry, specify firm*:	I	f "other," spec	cify*:			
Blinding to test result:		Duration of fo	llowup:			
* Use "NR" if not reported						
VI. Study Eligibility Crit	teria					
Inclusion criteria:	I	Exclusion crite	eria:			
	F	Exclude nre-ni	regnancy (type 1, 2	2)?		
			overt diabetes diagnosed during			
		regnancy?	•			
Did patients routinely under						
Dia patients featurely ander	igo carry testing for evert an	acces daring	programoj.			
VII. Screening and Diag	nostic Tests					
GCT/GST?	OGTT?	Ot	her test?	Specify:		
Test intervals:	Test intervals:	Te	st intervals:			
□Fasting; □1 hr; □ 2 hr;	Fasting; □1 hr; □	2 hr; □	□Fasting; □1 hr; □2 hr;			
\square 3 hr	\square 3 hr		3 hr	•		
Glucose load:	Glucose load:		ucose load:			
Time of test (wks):	Time of test (wks):		Time of test (wks):			
Criteria:	Criteria:		iteria:			
∐ADA, year:	☐ ADA, year:		ADA, year:			
\square CC, year: \square CC, year:			CC, year:			
∐NDDG, year:	☐ NDDG, year:		NDDG, year:			
∐WHO, year:	☐ WHO, year:		WHO, year:			
UOther1: , year:	Other1: , year:		Other1: , year:			
Other2: , year:	Other2: , year:	Other2: , year:				
□NR	□NR		NR			
Central lab? Notes	s:					

VIII. Study Arms

	Group 1	Group 2	Group 3	Group 4	Group 5	Group 6	Group 7	TOTAL
Group label								
GCT: Fasting	±	±	±	±	±	±	±	±
GCT: 1 hr	±	±	±	±	±	±	±	±
GCT: 2 hr	±	±	±	±	±	±	±	±
GCT: 3 hr	±	±	±	±	±	±	±	±
OGTT: Fasting	±	±	±	±	±	±	±	±
OGTT: 1 hr	±	±	±	±	±	±	±	±
OGTT: 2 hr	±	±	±	±	±	±	±	±
OGTT: 3 hr	±	±	±	±	±	±	±	±
Treatment status								
Glucose levels rep	orted in the fol	lowing units: \Box r	ng/dL; 🏻 mmol	/L Glucos	e levels reported	1 as: \square mean \pm S	D; \square median ± 1	QR
Are groups mutual								

IX. Baseline Characteristics

	Group 1	Group 2	Group 3	Group 4	Group 5	Group 6	Group 7	TOTAL
Pts enrolled, n								
Pts analyzed, n								
Withdrawals, n								
Age (yr),	±	±	±	±	±	±	±	±
\square mean \pm SD								
\square median ± IQR								
Prepregn. weight,	±	±	±	±	±	±	±	±
□lb; □kg								
\square mean \pm SD								
\square median ± IQR								
BMI, ∐	±	±	±	±	±	±	±	±
mean±SD								
\square median ± IQR								
SBP (mmHg),	±	±	±	±	±	±	±	±
\square mean \pm SD								
\square median \pm IQR								
	Group 1	Group 2	Group 3	Group 4	Group 5	Group 6	Group 7	TOTAL

White, n								
Black, n								
Hispanic, n								
Asian, n								
Other, n								
Gestation at time	±	±	±	±	±	±	±	±
of test (wk)								
\square mean \pm SD								
$\square \text{median} \pm \text{IQR}$								
Smoking, n								
Alcohol use, n								
Family history of								
diabetes, n								
History of GDM,								
n								
Parity, n	0	0	0	0	0	0	0	0
	1	1	1	1	1	1	1	1
	≥2	≥2	≥2	≥2	≥2	≥2	≥2	≥2
Parity	±	±	±	±	±	±	±	±
\square mean \pm SD								
$\square \text{median} \pm \text{IQR}$								
Comorbidities, n								
Comments								

X. Conclusions
Briefly paraphrase the author conclusions:
REFERENCES TO BE CHECKED:
ASSOCIATED PUBLICATIONS (list all separated by semi-colons):